Old Web
English
Sign In
Acemap
>
Paper
>
Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
Combined Ibrutinib and Venetoclax in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL)
2019
Nitin Jain
Michael J. Keating
Philip A Thompson
Jan A. Burger
Alessandra Ferrajoli
Zeev Estrov
Gautam Borthakur
Koichi Takahashi
Prithviraj Bose
Nathan Fowler
Tapan M. Kadia
Naval Daver
Marina Konopleva
Yesid Alvarado
Musa Yilmaz
Courtney D. DiNardo
Maro Ohanian
Naveen Pemmaraju
Elias Jabbour
Koji Sasaki
Rashmi Kanagal Shamanna
Keyur P. Patel
Jeffrey L. Jorgensen
Sa A. Wang
Naveen Garg
Xuemei Wang
Katrina Sondermann
Nichole Cruz
Chongjuan Wei
Ana Ayala
William Plunkett
Hagop M. Kantarjian
Varsha Gandhi
William G. Wierda
Keywords:
Oncology
Chronic lymphocytic leukemia
Ibrutinib
Refractory
Internal medicine
Medicine
Venetoclax
in patient
Immunology
Bone marrow
Neutropenia
Cytopenia
Chemotherapy regimen
Correction
Source
Cite
Save
Machine Reading By IdeaReader
0
References
7
Citations
NaN
KQI
[]